SS-31 (Elamipretide): what the published research shows
A research-focused summary of published SS-31 (elamipretide) studies, covering its identity as a mitochondria-targeted tetrapeptide and the cell, animal and clinical models in which it has been examined.
SS-31, also known as elamipretide, is a synthetic mitochondria-targeted tetrapeptide. Published work describes it as a therapeutic tetrapeptide with alternating cationic and aromatic residues, characterised by mitochondrial inner membrane binding and oxidative stress reduction [2]. The evidence block for this page does not supply a full sequence, molecular formula or molecular weight, so none are stated here. In the studies summarised below, the compound is supplied as a research reagent and applied to cultured cells, animal models, or administered under clinical trial protocols.
The mechanistic work centres on the mitochondrial inner membrane: SS-31 is studied for its interaction with cardiolipin-rich membrane environments and for its effects on mitochondrial function under stress. The sections that follow separate cell-culture findings from animal-model findings from clinical-trial activity, and each section names the model in which the observation was made.
Research Studies
SS-31 and radiation-induced senescence in cardiomyocytes
One study evaluated the effects of the mitochondrial-targeted peptide SS-31 (elamipretide) on radiation-induced cell senescence in cardiomyoblast H9C2 cells and in human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) [1]. Exposure to γ-radiation at doses of 2, 5 and 10 Gy inhibited H9C2 cell proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining, described in the paper as a gold-standard marker of senescence [1].
This is a cell-culture study. The findings describe behaviour of H9C2 cardiomyoblasts and hiPSC-CMs in vitro under ionizing radiation exposure, and do not establish an effect in intact animals or in humans.
SS-31 and α-synuclein membrane binding and aggregation
A separate study examined SS-31 in the context of α-synuclein, whose membrane binding and aggregation properties are closely associated with Parkinson's disease and a class of related syndromes termed synucleinopathy [2]. Using fluorescence correlation spectroscopy and fluorescence anisotropy, the work demonstrated that SS-31 displaces both wild-type and N-terminally acetylated α-synuclein from lipid membranes [2].
The same study investigated whether SS-31 mitigates the impairment of mitochondrial function induced by α-synuclein oligomers [2]. These are biophysical and cell-based measurements of peptide–membrane and peptide–protein interaction; they are not clinical outcomes.
SS-31 and mitochondrial dysfunction in aged female mice under nutritional stress
A comparative study in aged female mice under nutritional stress evaluated mitochondria-targeted approaches in the setting of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [4]. The paper frames MASLD as a major cause of cirrhosis, liver cancer and cardiovascular disease, and notes that early mitochondrial dysfunction drives lipid imbalance, inflammation and fibrosis, with no approved pharmacological treatments available [4]. The study compares mitochondria-targeted compounds, including SS-31 (elamipretide), in this model [4].
This is an animal study in aged female mice. Findings from it describe that model and are not transferable to human use.
SS-31 and Friedreich Ataxia vision loss: clinical trial activity
An investigator-initiated study of elamipretide in Friedreich Ataxia (FRDA) is registered to evaluate the safety, tolerability and activity of elamipretide in treating vision loss in FRDA [3]. This is a registered clinical trial record rather than a completed efficacy report; the entry describes the objective of the study, not a result.
SS-31 in the broader peptide-therapy literature for musculoskeletal injury
A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance situates peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and notes that their use in sports medicine is expanding, driven by demand for accelerated injury recovery and performance enhancement [5]. The review covers peptide drugs that have undergone rigorous assessment alongside others that have not [5].
This is a review-level source. It is cited here for context on how peptide therapies are classified and discussed in the sports-medicine literature, not as evidence of an SS-31 effect in musculoskeletal injury.
Model summary
The table below sets out the models in which SS-31 has been examined in the sources available for this page, so that the level of evidence behind each finding is explicit.
| Model or setting | What was measured | Evidence level | Source |
|---|---|---|---|
| H9C2 cardiomyoblasts and hiPSC-CMs exposed to γ-radiation | Proliferation, SA-β-gal senescence staining | In vitro | [1] |
| Lipid membrane systems with wild-type and N-terminally acetylated α-synuclein | Membrane displacement by fluorescence correlation spectroscopy and anisotropy | In vitro / biophysical | [2] |
| Mitochondrial function impaired by α-synuclein oligomers | Mitochondrial function | In vitro | [2] |
| Aged female mice under nutritional stress (MASLD model) | Comparative mitochondria-targeted evaluation | Animal | [4] |
| Friedreich Ataxia with vision loss | Safety, tolerability, activity | Registered clinical trial | [3] |
| Musculoskeletal injury and athletic performance | Review of approved and unapproved peptide therapies | Review | [5] |
What the evidence does not show
Across the sources available here, no completed human efficacy result for SS-31 is reported. The clinical entry is a registered study of safety, tolerability and activity in a specific FRDA population [3]. The mechanistic findings come from cultured cells and biophysical systems [1][2], and the comparative liver work comes from aged female mice [4]. The review source addresses peptide therapies as a class rather than SS-31 outcomes [5].
Reading the literature on mitochondria-targeted peptides
Two features of this literature are worth noting for anyone working through it. First, the same compound appears under both a code designation and a generic name, so searches should cover both. Second, the reported endpoints differ substantially by model: senescence staining and proliferation in cardiomyoblast culture [1], membrane binding and aggregation behaviour in α-synuclein systems [2], and comparative mitochondrial targeting in an aged-mouse liver model [4]. These endpoints are not interchangeable, and a result in one does not imply a result in another.
If you are reading this for personal health reasons
This material is sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence — https://europepmc.org/article/PMC/PMC13400571
- [2] Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function — https://pubmed.ncbi.nlm.nih.gov/42219795/
- [3] FRDA Investigator Initiated Study (IIS) With Elamipretide — https://clinicaltrials.gov/study/NCT05168774
- [4] Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress — https://pubmed.ncbi.nlm.nih.gov/42708867/
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/